Skip to main content
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 1877 ISIN · CNE100003FF7 HKEX Manufacturing
Open in API
Filings indexed 1,731 across all filing types
Latest filing 2026-01-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1877

About Shanghai Junshi Biosciences Co., Ltd.

http://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company established in 2012. It is dedicated to the discovery, development, clinical research, and commercialization of innovative therapeutics, prioritizing the creation of first-in-class and best-in-class drugs. The company utilizes a global integrated R&D system and proprietary full life cycle antibody development platform technology to build a diversified and complementary pipeline. Junshi Biosciences operates as a full-chain entity, integrating research, production, and commercialization capabilities to maintain global competitiveness in the biopharmaceutical sector.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it does not fit into specific categories like 'Share Issue' (which is for specific events) or 'Annual Report', and is a recurring regulatory filing mandated by the Exchange Listing Rules, it is classified as a Regulatory Filing (RNS).
2026-01-05 English
ANNOUNCEMENT - ADJUSTMENTS TO THE EXPECTED TIMETABLE FOR THE UTILIZATION OF PROCEEDS FROM THE 2022 ISSUANCE OF A SHARES
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai Junshi Biosciences regarding adjustments to the expected timetable for the utilization of proceeds from a previous A-share issuance. It details the status of specific projects, provides a table of financial utilization, and explains the rationale for the timeline extension. This falls under the category of capital and financing updates as it pertains to the management and allocation of raised capital.
2025-12-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-12-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-12-28 English
ACCEPTANCE OF REGISTRATION OF THE MEDIUM TERM NOTES BY THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the acceptance of registration for medium-term notes (debt financing) by the National Association of Financial Market Institutional Investors (NAFMII). It details the registered amount, validity period, and underwriting arrangements for future bond issuances. This falls under the category of company fundraising and financing activities.
2025-12-28 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PLAN FOR THE REDUCTION IN THE SHAREHOLDING OF THE SHAREHOLDERS HOLDING MORE THAN 5% OF THE SHARES
Major Shareholding Notification Classification · 95% confidence The document is an 'Overseas Regulatory Announcement' from Shanghai Junshi Biosciences Co., Ltd. regarding a 'Plan for the Reduction in the Shareholding of the Shareholders Holding more than 5% of the Shares'. This is a formal notification of a major shareholder's intent to sell a significant portion of their stake, which falls under the category of Major Shareholding Notification (MRQ) as it details changes in significant share ownership levels and the specific plan for such reduction.
2025-12-18 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.